MENU
+Compare
CASI
Stock ticker: NASDAQ
AS OF
Jan 17 closing price
Price
$2.62
Change
+$0.12 (+4.80%)
Capitalization
40.59M

CASI CASI Pharmaceuticals Forecast, Technical & Fundamental Analysis

a developer of pharmaceutical drugs for treating cancer and inflammatory diseases

Industry Biotechnology
CASI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for CASI with price predictions
Jan 08, 2025

CASI's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for CASI turned positive on December 24, 2024. Looking at past instances where CASI's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CASI's RSI Oscillator exited the oversold zone, of 48 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 61 cases where CASI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on January 03, 2025. You may want to consider a long position or call options on CASI as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CASI advanced for three days, in of 219 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 50-day moving average for CASI moved below the 200-day moving average on December 24, 2024. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CASI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CASI entered a downward trend on January 06, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.932) is normal, around the industry mean (14.744). P/E Ratio (0.000) is within average values for comparable stocks, (88.252). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.853). CASI has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (1.651) is also within normal values, averaging (264.079).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CASI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CASI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
CASI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a developer of pharmaceutical drugs for treating cancer and inflammatory diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
No. 81, Jianguo Road
Phone
+86 01065618789
Employees
243
Web
https://www.casipharmaceuticals.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FMAO26.700.41
+1.56%
Farmers & Merchants Bancorp
AXON593.898.05
+1.37%
Axon Enterprise
LNN133.041.76
+1.34%
Lindsay Corp
KTOS33.620.01
+0.03%
Kratos Defense & Security Solutions
JOB0.26-0.02
-6.12%
GEE Group

CASI and Stocks

Correlation & Price change

A.I.dvisor tells us that CASI and ASND have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CASI and ASND's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CASI
1D Price
Change %
CASI100%
+4.80%
ASND - CASI
33%
Poorly correlated
-2.65%
RIGL - CASI
29%
Poorly correlated
+16.02%
KALA - CASI
28%
Poorly correlated
+3.42%
ADCT - CASI
27%
Poorly correlated
+4.57%
IOVA - CASI
26%
Poorly correlated
+2.60%
More